Many viral oncolytic approaches against cancer are based on the ability of specific viruses to replicate in tumors expressing components of the constitutively activated Ras/mitogen-activated protein kinase (MAPK) pathways and/or inhibited or dysregulated alpha/beta interferon (IFN-␣/␤) response pathways. A major issue when considering these approaches is their applicability to tumors that lack activated Ras. To identify the effector mechanisms activated by oncolytic viruses, we investigated inhibition of proliferation of the prostate cancer line LNCap by the recombinant TR-NS1 influenza A virus, a genetically attenuated influenza A/PR8/34 virus expressing a truncated nonstructural protein (NS1) of 126 amino acids. LNCap cells lack constitutively activated MAPK, extracellular signal-regulated kinase (ERK), and p38 and are resistant to death by IFN-␣.
The delivery of a virus into malignant cells affords the opportunity of partial or complete tumor eradication (for excellent reviews, see references 21, 40, and 42) . One of the principles of cancer virotherapy is based on the findings that certain viruses preferentially replicate in tumor cells that lack either antiviral mechanisms or cellular inhibitors of virus replication (1, 5, 16, 45) . The antiviral mechanisms include the induction of alpha/beta interferon (IFN-␣/␤) production by the infected cell, followed by the transcriptional activation of the IFN-responsive antiviral genes. One of the key elements of the IFN-mediated antiviral response is the IFN-inducible, double-stranded RNA-activated protein kinase R (PKR). Tumor cells containing the activated Ras oncogene or Ras oncogene-activated mitogen-activated protein kinase (MAPK) pathway produce inhibitors of PKR (1, 5, 30) . Lack of active PKR in tumor cells results in increased sensitivity to viral replication and virus-induced lysis. Furthermore, activation of the immune system by infection of tumor cells with oncolytic viruses reportedly eliminated tumor cells (6, 17) . An important issue when considering virotherapy of cancer remains its applicability to tumor cells that lack constitutively activated Ras oncogenes or constitutively activated MAPK. Prostate tumors in American men infrequently express mutated or activated Ras (25) . In addition, the consequences of tumor apoptosis for activation of host defense by immune cells against human prostate tumors are unclear. The significance of the antitumor immune responses induced by virus-infected tumor cells has not been investigated in humans.
Influenza A viruses (IAV) are prototypes of the family Orthomyxoviridae and possess a genome of eight single-stranded RNA segments of negative polarity. It is known that IAV infection results in the induction of apoptosis of the host cells, both in cell culture and in vivo (23, 48) . The fact that wild-type IAV can infect and replicate in both tumor and untransformed cells makes its use as oncolytic virus unlikely. IAV encodes a nonstructural protein (NS1) involved in virulence and inhibition of the IFN-␣/␤ system during virus infection (20) . Interestingly, mutant IAV lacking the NS1 gene (⌬NS1) or expressing a truncated NS1 protein (TR-NS1) replicate poorly in normal cells but replicate significantly better in tumor cells containing activated Ras or dysregulated IFN responses (8, 32) . Growth factors, such as epidermal growth factor (EGF), mediate Ras activation by signaling through the EGF receptor 1 (EGFR1)/EGFR23Raf3Ras pathway. This pathway further activates MAPK kinases, extracellular signal-regulated ki-nase (ERK), p38, and Jun N-terminal protein kinase. It is unknown whether the presence of a Raf-Ras-activated system by growth factors allows infection and mediation of antitumor effects by influenza viruses with disabled or attenuated NS1.
To identify whether a recombinant influenza A/PR8/34 virus expressing a truncated NS1 protein of 126 amino acids (TR-NS1 virus) mediates inhibition of proliferation of human tumor cells lacking constitutively activated ERK, we investigated the outcome of infection of the human prostate cancer cell line LNCap by this virus. LNCap cells are androgen-dependent cells that lack constitutively activated ERK-1 in our experiments but proliferate in response to EGF and dihydroxytestosterone (7, 22) and activate ERK in response to EGF (7, 49) . For studies of the immune responses induced by virus infection, these cells possess the advantages that they express the oncogenic Her-2/neu proto-oncogene (HER-2) protein and the histocompatibility antigen HLA-A2. This not only allows characterization of the responses of cytotoxic T lymphocytes (CTL) to defined epitopes on a known tumor antigen (Ag) but also makes the findings relevant for the large number of patients who express HLA-A2. Inhibition of proliferation of LNCap cells following infection with TR-NS1 virus was dose dependent but was only transient. LNCap cells surviving the antiproliferative effects of TR-NS1 virus expanded in culture. However, the TR-NS1 virus-resistant tumor cells were completely eliminated after coculture with peripheral blood mononuclear cells (PBMC) and interleukin 12 (IL-12). This effect was at least partly mediated by lytic effectors, including tumorspecific CD8 ϩ cytolytic T cells, induced by TR-NS1 virus-infected LNCap cells (TR-NS1-LNCap) that recognized Ag on noninfected tumor cells. Our results indicate that TR-NS1 virus inhibited proliferation of a subpopulation of tumor cells lacking phospho-ERK (P-ERK), but in synergy with IL-12, activated cellular immunity to the tumor, which resulted in elimination of tumor cells.
MATERIALS AND METHODS
Chemicals, cytokines, and antibodies. Inhibitors of kinase pathways, U0126, PD098059 (ERK inhibitor), SB2035830 (p38 MAPK inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), emodine (tyrosine kinase inhibitor), farnesyl transferase (FT1) inhibitor (Ras inhibitor), and bis-indolyl-maleimide (BIM) (PKC inhibitor), were obtained from Calbiochem, Inc., and used at the indicated concentrations (1, 16) . EGF and Neu differentiation factor (NDF) were obtained from R&D Systems (Minneapolis, MN). IFN-␣, IFN-␥, IL-12, and IL-2 were obtained from Biosource (Camarillo, CA). IFN-␣, IL-12, IL-2, IFN-␥, and IL-12 (p70) detection kits were obtained from BD Pharmingen (San Diego, CA). Synthetic peptides E75 (HER-2 369-377), G60 (HES-1/, amino enhancer of split AES-1 125-135) (4, 18) , and M58 (influenza virus matrix protein M1 58-66), were prepared by the M. D. Anderson Peptide Synthesis Facility. Antibodies to ERK (p44/p42), p38, and AKT and corresponding antibodies to phospho-p44/ p42, phospho-p38, and phospho-Akt were obtained from Cell Signaling Technology, Inc. (39) . Antibodies against ␣-tubulin and against ␤-actin were obtained from Sigma Chemical Co. (St. Louis, Mo). The caspase inhibitors Z-IETDfluoromethyl ketone (fmk) (specific for caspase-8), Z-LEHD-fmk (specific for caspase-9), and EDVE-fmk (specific for caspase-3) were purchased from R&D Systems. Empty recombinant soluble dimeric HLA-A2-immunoglobulin G1 (IgG1) molecules, designated as "dimers," monoclonal antibodies (MAb) used for detecting surface CD8, isotype MAb controls, fluorescein isothiocyanate (FITC)-and phycoerythrin-conjugated MAb, and all specific Ig controls were obtained from BD Pharmingen. Ab against IAV hemagglutinin (HA) was purchased from the NIH repository.
Cell culture. The prostate cancer cell lines LNCap and PC-3 (7, 22) were obtained from ATCC. Ovarian lines SKOV3, 2774, and the breast cancer line SKBR3 have been described in our previous papers (4, 18) . Cells were grown in the recommended culture medium with 10% fetal calf serum (FCS). PBMC were isolated from healthy donors and separated into the plastic-adherent and nonplastic-adherent fractions. The non-plastic-adherent fraction contained 95% CD3-positive cells. The plastic-adherent PBMC were cultured in medium containing granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 for 5 days. Culture in GM-CSF and IL-4 resulted in immature monocyte-derived dendritic cells (MDC) as we described previously (14, 31) . Unfractionated and non-plastic-adherent PBMC were stored frozen in liquid nitrogen until use.
Viruses. The generation, growth, and titration of TR-NS1 and ⌬NS1 viruses were performed according to the methods previously described (14, 46) . TR-NS1 and ⌬NS1 viruses and their parental wild-type influenza A/PR8/34 virus (PR8) were grown in the allantoic cavities of 7-day-old embryonated chicken eggs.
Characterization of the virus effects on proliferation of tumor cell lines. Tumor cells were plated at various numbers in 24-or 48-well plates. They were infected either with parental PR8 or with TR-NS1 viruses at various multiplicities of infection (MOIs) in serum-free medium. After 2 h of infection, the medium was removed and cells were covered with fresh medium containing 10% FCS. To identify live cells at indicated time points, cells were washed, detached with trypsin, and counted in the presence of trypan blue. To determine the sensitivity of LNCap cells to cytokines, they were incubated either in 24-or 96-well plates with various concentrations of IFN-␣ (4,000 and 1,000 U/ml), IL-12 (200 IU/ml), and IFN-␥ (400 and 2,000 pg/ml).
Inhibition of tumor cell proliferation was determined with the classical 3-(4,5-dimethylthriazol-2-yl) 2,5-diphenyl-tetrazolium bromide (MTT) assay as previously described (19) using an MTT cell proliferation assay kit from Molecular Probes (Eugene, OR). Live cells reduce MTT to a strongly pigmented formazan product, whereas dead cells do not. Inhibition of proliferation of tumor cells by TR-NS1 virus was determined from the equation percent inhibition of optical density at 570 nm (OD 570 ) ϭ (A Ϫ B)/(A ϫ 100), where A is the optical density of wells containing tumor cells that were not infected with virus and B is the optical density of wells treated with virus.
To eliminate the effects of tumor cell stimulation by growth factors present in the FCS, in some experiments, cells were treated by first decreasing serum concentration to 5%, followed by culture in low FCS concentration (0.3 to 0.5%) for 16 to 20 h before the addition of virus, growth factors EGF and NDF, or tyrosine kinase inhibitors as described previously (10) . For analysis of formation of tumor cell-leukocyte clusters, 5 ϫ 10 4 infected or mock-infected tumor cells were incubated with 3 ϫ 10 6 PBMC. Cultures were examined with an inverted microscope (Nikon TMS-F) and recorded using a NIKON Cool Pix 995 digital camera. Tumor cells were considered to induce clusters only when they were completely surrounded by leukocytes.
In vitro induction of CTL by TR-NS1 virus-infected tumor cells. LNCap, SKOV3, and SKBR3 cells were plated at a density of 5 ϫ 10 4 cells/well in 24-well plates, allowed to attach for 2 to 3 h, and then infected with TR-NS1 virus. Two hours later, the infection medium was removed, the cells were rinsed with phosphate-buffered saline two times, and RPMI 1640 medium containing 10% FCS (complete RPMI 1640 medium) was added to the wells. A total of 3 ϫ 10 6 freshly isolated PBMC were added 2 h later, followed by IL-12 at 100 pg/ml and/or EGF plus NDF at 60 ng/ml as indicated (10) . IL-2 at 150 IU/ml was added 24 h later. When MDC were used as antigen-presenting cells (APC), they were added to the TR-NS1 virus-infected tumor cells before addition of T cells. In some experiments, tumor necrosis factor alpha was added to stimulate MDC maturation (2, 10) . Cells were maintained in culture for 6 to 8 additional days. The presence of T cells expressing T cell receptors (TCR) specific for the CTL epitopes from HER-2 (E75), AES-1/2 (G60), and influenza virus matrix (M58) was determined using HLA-A2-peptide (dE75, dG60, and dM58) dimers on day 6 as described previously (26) . Negative-control dimers consisted of HLA-A2-IgG1 dimeric molecules that were not pulsed with peptide before they were used for staining. Negative-control dimers were designated dNP.
CTL assays were performed on day 8 after priming as previously described using 51 Cr-labeled tumor cells as the targets (2) . Ag specificity of CTL was determined using inhibitory targets in the same experiment. Inhibitory targets were T2 cells pulsed with peptide E75 or not pulsed with peptide and were designated T2-E75 and T2-NP, respectively.
Immunoblot analysis. TR-NS1 virus was added at a final MOI of 3 PFU/cell on monolayers of LNCap cells and incubated with tumor cells for 60 min. Control cultures were mock infected and treated under the same conditions as the cultures of infected cells. Cells were then washed in cold phosphate-buffered saline and lysed in lysis buffer. Cell lysates were adjusted to the same protein concentration and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nylon membranes, and blotted with corresponding antibodies as previously described (26, 39) . Scanning densitometry was performed as previously described using a Hewlett-Packard scanner. The results
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were analyzed using Scion Image software for Windows (Scion Corporation, Frederick, MD). Cell cycle and apoptosis analysis. Uninfected LNCap cells or cells infected with TR-NS1 or PR8 virus were stained with annexin and propidium iodide using the TACS-annexin V-FITC apoptosis detection kit and were analyzed by flow cytometry using a Becton Dickinson FACSCalibur with Cell Quest software (Becton Dickinson) (26, 39) .
RESULTS

TR-NS1 virus inhibited proliferation of LNCap cells.
To address whether TR-NS1 virus inhibited the proliferation of prostate cancer line LNCap, LNCap cells were infected with TR-NS1 virus over a range of viral doses. Inhibition of proliferation of LNCap cells was viral dose dependent and was as high as 85% (Fig. 1A) . Addition of EGF after TR-NS1 virus infection slightly decreased the virus-induced inhibition of tumor cell proliferation. LNCap cells resistant to TR-NS1 virus infection at 48 h expanded; therefore, the apparent inhibitory effects of TR-NS1 virus were weaker at 120 h than at 48 h (compare Fig. 1A and B). To distinguish whether the effects of TR-NS1 virus infection differed in P-ERK ϩ PC-3 cells, the experiments were repeated with PC-3 cells under the same conditions. PC-3 cells are androgen independent but express a constitutively activated MEK3ERK pathway. TR-NS1 virus inhibited PC-3 cell proliferation by more than 90% in the presence of EGF (data not shown). The results of these experiments together show that TR-NS1 virus infection eliminated the majority of prostate tumor cells. Although only a small part (5 to 15%) of LNCap cells survived TR-NS1 virus infection, they expanded in culture. Exogenous EGF and NDF did not render the LNCap cells more susceptible to virusmediated death. To the contrary, they induced a slight increase in resistance of LNCap cells to TR-NS1 virus-mediated death. This observation raised the question of how prostate tumor cells were eliminated.
In order to compare wild-type and TR-NS1 viruses with respect to their ability to inhibit tumor cell proliferation, the experiments were repeated with TR-NS1 and parental PR8 viruses in parallel. Figure 1C shows that TR-NS1 virus had stronger oncolytic effects than parental PR8 virus did. Figure  1D shows that at 50 PFU per cell and EGF, the increase in the number of TR-NS1 virus-infected cells was smaller (1.3-fold) than those of PR8 virus-infected cells and noninfected LNCap cells. To address whether these differences were due to differences in infectivity, LNCap cells were infected with PR8 and TR-NS1 viruses (50 PFU/cell) and expression of viral HA was determined 18 h later. Figure 1E , F, and G show high and We have also determined the percentage of apoptotic LNCap cells after infection with wild-type PR8 and TR-NS1 viruses by annexin V staining (Fig. 2E, F, and G) . The number of annexin-positive cells in early apoptosis increased by 97% in cultures infected with TR-NS1 virus but only by 50% in cultures infected with PR8 virus compared with noninfected cells. Our results suggest that the TR-NS1 virus induced higher apoptosis than the wild-type PR8 virus, consistent with the proposed attenuation of apoptosis by NS1 during virus infection (50) . In summary, TR-NS1 virus infected the majority of tumor cells, induced apoptosis in a subpopulation of these cells, and inhibited tumor cell proliferation. However, these effects were transient and surviving cells expanded.
TR-NS1 virus activated ERK-1 in LNCap cells.
To identify signaling pathways mediating inhibition of proliferation, LNCap cells were pretreated with the PKC inhibitor BIM, the MEK-ERK inhibitor U0126, and caspase inhibitors at the time of infection with 16 PFU of TR-NS1 virus per cell (9) . Pretreatment with BIM resulted in less inhibition of proliferation by TR-NS1 virus, as detected by the MTT assay at 48 h postinfection, indicating a role for PKC activation in LNCap infection. The MEK3ERK inhibitor U0126 had similar (although weaker) blocking of inhibitory effects than the PKC inhibitor did. The caspase-3 and caspase-9 inhibitors were also able to reduce the antiproliferative effects of TR-NS1 virus infection, but they were significantly less efficient than U0126 (Fig. 2H) . Thus, maximum antiproliferative effects mediated by TR-NS1 virus require PKC and MEK-ERK activities, as well as the induction of caspase pathways.
It has previously been reported that IAV infection induces ERK activation (35) . The results in Fig. 2I show that interaction of TR-NS1 virus with LNCap cells for 1 h activated ERK in these cells. The levels of phosphorylation of ERK-1 were significantly higher than the levels of phosphorylation of ERK-2, suggesting that virus infection preferentially activated ERK-1. This is evidenced by the phospho-ERK (P-ERK)/ERK ratios. The P-ERK-1/ERK-1 ratios in uninfected and infected cells were 0.026 and 0.746, respectively, an increase of more than 20-fold. The P-ERK-2/ERK-2 ratios in uninfected and infected cells were 0.235 and 0.815, respectively, which represented an increase of less than fourfold. The total amounts of ERK-1 and ERK-2 were similar in uninfected and TR-NS1 virus-infected cells compared with actin.
Human PBMC and IL-12 induced complete elimination of TR-NS1 virus-infected LNCap cells. Since the inhibition of proliferation of LNCap cells by TR-NS1 virus was transient, the elimination of tumor cells by direct viral infection alone was not effective. In addition to directly lysing tumor cells, oncolytic viruses are known to activate specific immune responses with antibody responses to the virus being dominant. Induction of cellular responses to tumor-specific antigens would require the presence of proinflammatory cytokines, such as IL-12, which is essential for CD8 ϩ cell differentiation and natural killer (NK) cell activation. To address whether TR-NS1-LNCap cells stimulated release of endogenous IL-12 in PBMC, LNCap cells were infected with increasing doses of TR-NS1 virus and incubated with either freshly isolated PBMC (containing M and DC) or nonadherent PBMC (lacking M and DC) at two stimulator/responder ratios. M and DC are the main producers of IL-12. The results in Fig. 3A and B show that TR-NS1-LNCap cells did not induce an increase in the IL-12 level above the background level at 24 or 48 h, indicating that these infected cells were weak inducers of IL-12. Similar IL-12 levels were observed for TR-NS1-infected PBMC (Fig. 3C) . The same PBMC responded with high levels of IL-12 to positive-control inducers, such as muramyl dipeptide and staphylococcal peptidoglycan (Fig. 3D) .
Despite weak or no induction of IL-12, TR-NS1-LNCap cells attracted leukocytes, which formed large clusters with tumor cells within 24 h (Fig. 3E) . Cluster formation was not observed with uninfected tumor cells (Fig. 3F) . Therefore, chemoattraction and cell aggregate formation were due exclusively to virus infection. In separate experiments, we also observed the formation of clusters between MDC infected with PR8 virus or other influenza virus variants and leukocytes (data not shown). To address whether this effect was amplified by IL-12, IL-12 was added to all cultures (uninfected and infected). IL-12 did not induce cluster formation in cultures of uninfected LNCap cells and PBMC (data not shown). These results were confirmed with three additional healthy donors and with ovarian (SKOV3) and breast (SKBR3) cells (data not shown). It should be noted that LNCap cells are HLA-A2 Table 1 ). The level of IFN-␥ increased by more than 3-fold when TR-NS1-LNCap cells were used as stimulators and by more than 12-fold when IL-12 was added to the cultures. Therefore, infection of LNCap cells with TR-NS1 virus activated IFN-␥ production in PBMC even in the presence of EGF plus NDF. Exogenous IL-12 acted as a cofactor to enhance IFN-␥ production. The results were confirmed with PBMC from a second donor. Figure 3A shows that the amount of IL-12 produced by PBMC in response to high numbers of TR-NS1-LNCap cells was borderline (10 pg/ml). Thus, it is likely that exogenous IL-12 at 200 pg/ml compensated for the low endogenous production of IL-12 in response to virus. To address whether IFN-␥ and IL-12 could eliminate tumor cells, IFN-␥ at the concentration detected to be produced by the same number of PBMC (400 pg/ml) and IL-12 at the concentration used as a cofactor for induction of IFN-␥ (200 pg/ml) were added to uninfected LNCap cells. The effects of cytokines on the proliferation of tumor cells were determined 3 days later. Figure 4A shows that these cytokines together eliminated less than 50% of the tumor cells. It should be mentioned that the IFN-␣-mediated de- 
FIG. 3. (A to D) TR-NS1-LNCap cells and TR-NS1 virus are weak inducers of IL-12 in PBMC. LNCap cells were infected with TR-NS1 virus at the indicated MOI for 4 h. Freshly isolated PBMC (A) or nonadherent PBMC (B) were added at a stimulator/responder ratio of 1:16 (circles) or 1:32 (squares). IL-12 production was determined 24 h (open symbols) and 48 h after stimulation (closed symbols). The number of responders in each well was kept the same at 500,000 PBMC. (C) PBMC were incubated directly with TR-NS1 virus using the same conditions as in panel A, but in the absence of LNCap cells. (D) For a positive control, the PBMC were induced by muramyl dipeptide (MDP) and staphylococcal peptidoglycan (PGN). (E and F) TR-NS1-LNCap cells attract leukocytes from PBMC. Uninfected LNCap cells (F) and TR-NS1-LNCap cells (E) are shown. (G) Addition of IL-12 and PBMC completely eliminated TR-NS1-LNCap cells. LNCap cells were infected
a A total of 4.5 ϫ 10 4 LNCap cells uninfected or infected with TR-NS1 (32 PFU/cell) were plated in a 24-well plate. EGF and NDF were added to each well at a final concentration of 60 ng/ml. A total of 3 ϫ 10 6 freshly isolated, uncultured PBMC were added to each well 2 h later, followed by 2 IU/ml (200 pg/ml) of IL-12. The stimulator-to-responder ratio was 1:67. Supernatants were collected 20 h later and used for detection of IFN-␥ using specific human IFN-␥ enzyme-linked immunosorbent assay. (29) . In addition, we wanted to know whether TR-NS1-LNCap cells activated CD8 ϩ cells that recognized antigens presented by the tumor cells. For this purpose, we performed cytolytic assays using noninfected LNCap cells as the targets. To account for lytic effects mediated by CD8 ϩ cells, inhibition of tumor lysis by CD8-specific Ab was determined in parallel. Effectors were HLA-A2 ϩ PBMC stimulated with uninfected LNCap (designated LNCap-ST) and with TR-NS1-LNCap (designated LNCap-TR-NS1-ST). Lysis of LNCap cells by LNCap-ST effectors was not inhibited by CD8-specific MAb. Lysis of LNCap cells by TR-NS1-LNCap-ST effectors was partially inhibited by anti-CD8 Ab (Fig. 4B) .
To verify that LNCap-TR-NS1-ST effectors recognized Ag generated by the endogenous pathway, we used TR-NS1-LNCap cells as the targets. LNCap-TR-NS1-ST effectors mediated higher levels of lysis of TR-NS1-LNCap cells than LNCap-ST effectors at the same effector-to-target cell ratio (Fig. 4C) . Compared with LNCap-ST effectors, the higher levels of lysis of TR-NS1-LNCap cells by LNCap-TR-NS1-ST effectors were all due to the CD8 ϩ effectors. In summary, the results are consistent with both uninfected and TR-NS1 virus-infected LNCap-mediated activation of a significant number of tumor-lytic NK and NK-T cells; however, only LNCap-TR-NS1-ST cells activated additional cytolytic CD8 ϩ cells, which lysed more tumor cells. The results also indicate that cytolysis was not due only to alloreactive effectors activated by partially HLA-matched tumor cells, since LNCap cells (uninfected and infected) were used for activation of effectors from the same donor.
TR-NS1-LNCap cells expanded Ag-specific CD8
؉ cells. To determine whether Ag-specific CD8 (Fig. 5B) .
To address whether poor expansion of M58-TCR ϩ cells was due to anergy or an absence of M58-TCR ϩ cell precursors, DC from the same donor were used as APC to stimulate autologous T cells. M58-TCR ϩ cells were present in the PBMC of this donor with a high frequency (0.70%). M58-TCR ϩ cells increased by 3.74-fold when stimulated by TR-NS1-DC (see Fig. S1 in the supplemental material) . Therefore, the TR-NS1-LNCap cells as the APC system were less stimulatory than the TR-NS1-DC cells were.
In order to determine whether M58 was dominant compared with E75, DC from the same donor were infected with KIF-NS virus (KIF-NS-DC). KIF-NS is identical to the TR-NS1 virus, except that it expresses the E75 epitope as part of the viral neuraminidase protein (14) . KIF-NS-DC were used to stimulate autologous isolated T cells. The results show that the activating ability of M58 and E75 was similar when presented by the endogenous pathway by the same virus in the same professional APC (see Table S1 in the supplemental material). We also investigated whether free peptides E75 and M58 presented by DC mediated similar effects in activation of memory cells. We stimulated in parallel freshly isolated PBMC from three additional HLA-A2 ϩ healthy donors with these peptides in the absence of IL-2 and IL-12 to avoid activation of naïve cells. All four donors responded to M58 by producing IFN-␥ in the range 24 to 150 pg/ml, while responded to E75 by producing IFN-␥ in the range 2.5 to 7.9 pg/ml. This indicated that there is a higher frequency of IFN-␥-producing memory effectors to M58 but a lower frequency of IFN-␥-producing memory effectors to E75 (see Table S2 in the supplemental material). The reasons for E75 dominance in LNCap-TR-NS1 crosspriming are unknown. LNCap cells overexpress HER-2 protein (not shown). It is possible that HER-2 protein already being present in sufficiently high levels provided significantly higher levels of precursors of E75 for CTL priming than IAV matrix protein. It is also possible that a sufficient amount of IAV matrix has not been synthesized in our experimental system.
In an additional experiment, using PBMC from a second HLA-A2 ϩ donor as responders, we compared the immunogenicity of TR-NS1 virus with ⌬NS1 (completely lacking the NS1 gene), KIF-NS (TR-NS1 virus expressing the E75 epitope), and PR8 (wild-type) influenza viruses (Fig. 5C ). Parental PR8 virus was less effective than the NS1 mutant viruses in activation of E75-TCR ϩ cells, while KIF-NS virus was the most effective in expanding E75-specific cells. Thus, the tumor cells lysed by TR-NS1 virus in the first 20 h after infection were most likely the source of E75 peptides.
TR-NS1 virus induced death of breast and ovarian tumors expressing activated HER-2 and activated CD8
؉ cells recognizing CTL epitopes from the HER-2 protein. To address whether TR-NS1 virus was oncolytic for tumor cells that express activated ERK and activated HER-2, we determined the ability of this virus to eliminate tumor cells of the cell lines SKBR3 (a breast cancer line) and SKOV3 (an ovarian cancer line). Both lines overexpress HER-2 protein at high levels. SKBR3 and SKOV3 cells were more sensitive to oncolysis than LNCap cells, and they were completely eliminated 72 h after infection with TR-NS1 virus (data not shown).
The results in Fig. 4 and 5 raised the question whether CTL could have been activated by cross-priming. Since both SKBR3 and SKOV3 cells are HLA-A2 Ϫ , we addressed this question by determining whether TR-NS1 virus-infected SKBR cells (TR-NS1-SKBR3) and TR-NS1 virus-infected SKOV3 cells (TR-NS1-SKOV3) (32 PFU/cell) expanded and activated indicator HLA-A2 ϩ E75-TCR ϩ cells in the presence of HLA-A2 ϩ DC. Purified HLA-A2 ϩ DC were added to HLA-A2 Ϫ TR-NS1-SKBR3 and HLA-A2
Ϫ TR-NS1-SKOV3 cells. Four hours later, purified autologous HLA-A2 ϩ T cells were added to the cultures, followed by IL-12. To determine the presence of Ag-specific cells in these cultures, for indicators, we used T cells expressing TCR specific for the HER-2 protein HLA-A2 epitope E75 (E75-TCR ϩ ) and T cells expressing TCR specific for an epitope derived from the product of the "Hairy" HES/ AES-1/2 gene, which is associated with the Notch receptor (G60-TCR ϩ ). Figure 6A to E show that there were more E75-TCR ϩ cells than G60-TCR ϩ cells in both TR-NS1-SKBR3 and TR-NS1-SKOV3 cocultures. There were also more E75-TCR ϩ cells present in the CD8 lo population that expresses low levels of CD8 (MFI of CD8, 10 1 to 10 2 ) than in the CD8 hi (expressing high level of CD8) population (MFI of CD8, Ͼ10
2 ). There were also more E75-TCR ϩ cells in TR-NS1-SKBR3-stimulated CD8 ϩ cells than in TR-NS1-SKOV3-stimulated CD8 ϩ cells, indicating that cross-priming by DC was not only effective but was also dependent on the amount of the precursor protein in the tumor cells. SKBR3 cells express larger amounts of HER-2 protein than SKOV3 cells do (not shown). Internal-control G60-TCR ϩ cells were present in smaller numbers than E75-TCR ϩ cells, both in the CD8 lo cells and in the CD8 hi cells (Fig. 6D and E) . To address whether CTL activated by TR-NS1-SKOV3 were Ag specific and functional, we determined the ability of E75-pulsed T2 cells (HLA-A2 ϩ ) to inhibit lysis of SKOV3 and SKOV3.A2 cells. SKOV3.A2 cells express a transfected HLA-A2 molecule; therefore, in contrast with parental SKOV3 cells, they were HLA-A2 matched with the effectors 
DISCUSSION
In this paper we report several novel findings regarding the ability of a recombinant attenuated IAV, TR-NS1 virus, to activate cellular immune responses against tumors resulting in tumor elimination. These findings were obtained with prostate tumor cells of the line LNCap, which is a poor host for TR-NS1 virus-mediated oncolysis, and were confirmed with breast and ovarian tumor cells, which are good hosts for replication of IAV variants expressing a truncated NS1 protein (TR-NS1) or lacking the NS1 protein (⌬NS1). ⌬NS1 and other oncolytic viruses have been reported to induce irreversible inhibition of growth of tumors that express constitutively activated Ras3MAPK pathways and/or have defects in the IFN-␣/␤ response systems (8, 24, 32) . We found that TR- ϩ CTL. CD8 ϩ Tcell activation was at least partly mediated by cross-priming by APC and not only directly by the tumor (alloreactivity), since CD8 ϩ cells generated by stimulation with TR-NS1-SKOV3 mediated Ag-specific HLA-A2-dependent lysis of the uninfected HLA-A2 ϩ tumor cells. We found that both wild-type PR8 and TR-NS1 viruses were able to infect the majority of the tumor LNCap cells. PR8 virus replicated better in LNCap cells as indicated by the higher level of expression of HA (Fig. 1F and G) . Although both wild-type and TR-NS1 viruses are oncolytic, an attenuated virus, such as TR-NS1 virus (46) , is preferred as an oncolytic agent to reduce the potential side effects of wild-type virus infection in nontransformed cells. Interestingly, TR-NS1 virus is more attenuated in normal cells than in tumor cells, and it is known to have preferential specificity for replication in transformed cells (32) . In addition, TR-NS1 virus was more oncolytic than the parental PR8 virus (Fig. 1C and D) . This effect may be due to the truncated NS1 protein, which might have an impaired function in apoptosis inhibition (50) . Consistent with this, TR-NS1 virus infection induced higher levels of apoptosis in LNCap cells than PR8 virus did (Fig. 2) . Further studies are needed to address this point. Our results have revealed antitumor effector pathways activated in virus-infected tumor cells that lack constitutively activated ERK (Fig. 7) . We propose that TR-NS1 virus activated ERK-1 in these cells, more likely as a consequence of activation of PKC at the time of infection (41) . ERK activation might allow for viral replication and induction of apoptosis in a proportion of tumor cells. APC, such as macrophages (M) and DC, were attracted to the tumor cells and most likely phagocytosed dying TR-NS1 virus-infected tumor cells. Peptides from tumor proteins presented by APC to T cells induced CTL expansion and differentiation, which resulted in tumor lysis.
How tumor cells were selected for death by virus remains unclear. Cell cycle analysis did not indicate that TR-NS1 virus targeted cells in a particular phase of the cell cycle. We found a proportionally higher decrease in the number of cells in the S phase than in the G 1 phase; this effect was stronger at higher TR-NS1 virus MOIs. It is also possible that some tumor cells in G 1 phase were more sensitive to death by TR-NS1 virus than, for example, cells in G 2 /M phase.
How PKC3ERK and MEK-ERK activation connected to death pathways in TR-NS1 virus-infected tumor cells is unknown. The mitogenic or death effects of ERK were reported to be dependent on the agonist (growth factor, tetradecanoyl phorbol acetate, or virus) and the duration and intensity of ERK activation (11, 44) . It is also possible that IAV variants activate additional signaling pathways mediated by other kinases or MAPKs other than ERK (28) . In separate experiments using low doses of TR-NS1 virus, which did not activate ERK-1/2, we noted that AKT was constitutively activated in LNCap cells, but its level of phosphorylation was not affected by TR-NS1 virus, while p38MAPK remained inactive (lacked phosphorylation) before and after TR-NS1 virus infection (S. Sellapan and C. G. Ioannides, unpublished observations). A recent study indicates that a related virus, reovirus, required activated Ras3p38MAPK pathway to infect nonpermissive fibroblasts (33) . We do not know at this time whether these conclusions could be extended to TR-NS1 virus infection of LNCap tumor cells. Another recent study demonstrated strong tropism of IAV for tumors transformed by activated Raf (34) . Since LNCap cells express high levels of HER-2, it is possible that the HER-23Ras3Raf pathway may be activated and act synergistically with IAV.
Our results indicate that the virus-initiated tumor cell elimination was amplified by activation of NK cells and Ag-specific CD8 ϩ cells (Fig. 7) . Ag-specific CD8 ϩ cells were activated by APC by cross-priming, i.e., presentation of peptide fragments from the apoptotic proteins by specialized APC. Activation of APC could have been mediated by TLR-dependent and -independent pathways. An impaired NS1 function might have been resulted in higher activation of DC. In fact, a recombinant IAV without NS1 induced higher activation of DC than wild-type virus did (27) . However, further experimentation is required to prove this hypothesis. Activation and expansion of CD8 ϩ T cells was enhanced by the polarizing cytokine IL-12. IAVinfected tumor cells were weak inducers of IL-12. APC, such as DC, produce IL-12 if stimulated properly; however, the level of IL-12 produced by differentiated, mature DC is much higher than that produced by immature DC. In our studies, for APC, we used either unseparated PBMC or immature MDC. An explanation for the observed effects is that in these systems, APC did not completely differentiate within 16 to 20 h and that exogenous IL-12 compensated for the lack of endogenous IL-12.
The CTL priming effects mediated by TR-NS1-LNCap were confirmed using SKBR3 breast and SKOV3 ovarian tumor cell lines. Both cell lines express constitutively activated HER-2 kinase and activated ERK. Compared to LNCap cells, both SKBR3 and SKBOV3 cells were more likely to die after TR-NS1 virus infection. Death induced by TR-NS1 virus was prevented mainly by the MEK3ERK inhibitor U1026, but not by the ERK inhibitor PD08909, indicating an event upstream of ERK was required. Inhibitors of p38 MAPK, Jun N-terminal protein kinase, and phosphatidylinositol 3-kinase had weak and insignificant protective effects. However, it is possible that at higher concentrations these inhibitors can be protective, although the functional significance of this protection needs to be determined.
The finding that attenuated IAV, such as TR-NS1 virus with weak oncolytic properties, can induce, with help from IL-12, tumor-lytic CTL after infection of nonpermissive tumors is novel for the human tumor system. Multiple attenuation markers were inserted in this recombinant virus, including singleamino-acid changes in the PB2 and PA polymerase genes and the nucleoprotein gene and a truncation in the NS1 gene that resulted in loss of virulence in mice (14, 46) . Similar NS1 truncations result in attenuation of primary isolates of influ- (36, 43) . Thus, the use of TR-NS1 virus in humans is likely to be safe.
In our experiments, we used EGF at concentrations 100-to 200-fold higher than the concentrations of IL-12. Complete inhibition of antitumor cell proliferation effects of TR-NS1 virus by EGF was not observed. A new generation of RNA vectors can direct the cellular responses toward CTL of the desired specificity, e.g., prostate tumor Ag (3), by expressing the protein in one vector and IL-12 from another vector (37) . Integration of the growth-inhibitory and T-cell-activating pathways in one vector might amplify the anticancer effects of the virus. Such studies are ongoing in our laboratory.
